Corcept Therapeutics
CORT · NASDAQ
Bulios Fair Price
$105.56
8.1% downside
Current Price
$114.86
According to Bulios Fair Price, CORT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Corcept Therapeutics Incorporated (CORT) is an American biotechnology company specializing in research, development, and commercialization of drugs for the treatment of endocrine and psychiatric disorders. With activities in biotechnology and pharmacology, Corcept Therapeutics is a key player in the world of innovative treatment approaches. Their research focuses on discovering new treatment methods and therapies for patients with endocrine and psychiatric disorders, including Cushing's syndrome. The company aims to provide modern treatment solutions and improve the quality of life for patients. Corcept Therapeutics is characterized by expertise in pharmacology and endocrine medicine. Corcept Therapeutics Incorporated (CORT) shares could be suitable for investors looking for an investment opportunity in the biotechnology and pharmaceutical sector with a company that specializes in innovative treatment approaches and therapies for patients with endocrine and psychiatric disorders.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Joseph K. Belanoff
Employees
730
Headquarters
Redwood City
Upcoming events
Earnings
Upcoming earnings report